RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -47.64% | -47.64% | -- | -- | -33.84% |
| Total Depreciation and Amortization | -16.07% | -16.07% | -- | -- | -59.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.95% | 143.95% | -- | -- | 123.98% |
| Change in Net Operating Assets | -71.38% | -71.38% | -- | -- | -132.84% |
| Cash from Operations | -17.42% | -17.42% | -- | -- | 46.81% |
| Capital Expenditure | -250.00% | -250.00% | -- | -- | -300.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 9,400.00% | 9,400.00% | -- | -- | -300.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 57.14% | 57.14% | -- | -- | 54.35% |
| Issuance of Common Stock | 58.35% | 58.35% | -- | -- | -58.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 65.05% | 65.05% | -- | -- | -58.75% |
| Foreign Exchange rate Adjustments | -111.11% | -111.11% | -- | -- | 250.00% |
| Miscellaneous Cash Flow Adjustments | 59.48% | 59.48% | -- | -- | -- |
| Net Change in Cash | 167.85% | 167.85% | -- | -- | -202.52% |